MichaelPatrickCastroMD

PubMed

• 4 citations
  A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine.
  Pauline Latzer, Henning Zelba, Florian Battke, Annekathrin Reinhardt, Borong Shao
  Nature Communications. 2024-08-11
• Network targeting combination therapy of synthetic lethal vulnerabilities indeficient glioblastoma: A case report.
  Michael P Castro, Kristin Dittmar
  Neuro-Oncology Advances. 2023-12-10
• Network-targeting combination therapy of leptomeningeal glioblastoma using multiple synthetic lethal strategies: a case report.
  Michael P Castro, Bence Sipos, Saskia Biskup, Nina Kahn
  Frontiers in Oncology. 2023-01-01

Journal Articles

• Targeting the Complex Protein Network of MYCN-amplified Anaplastic Ependymoma: A Case Report.  
  Michael Castro, J Cell Signal. 2022;3(4):179-192, 12/2022
• Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy—a case report.  
  Castro MP, Khanlou N, Fallah A, Pampana A, Alam A, Lala DA, Roy KGG, Amara ARR, Prakash A, Singh D, Behura L, Kumar A, Kapoor S., Ann Transl Med 2022, 12/2022
• Unintended effects of proton pump inhibitors (PPIs) in patients with glioblastoma (GBM): A double-edged sword  
  Michael Castro, Neuro-Oncology Practice, Volume 9, Issue 4, August 2022, Pages 344–345, 8/2022
• Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magni...  
  Castro, M., Pampana, A., Alam, A. et al., J Neurooncol (2021), 1/2021
• Utility of Serial Transcriptomic Analyses to Characterize the Resistome and to Refine Treatment Selection for Metastatic Colon Cancer: Case Report.  
  Michael P. Castro, Mohammad Afshar, Coralie Williams, et al., Clinical Colorectal Cancer 2021, 20(1): 96-99., 2021
• Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinom...  
  Castro MP and Goldstein N, Journal for ImmunoTherapy of Cancer, 12/15/2015
• Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with...  
  Michael P. Castro, Bradford P. Whitcomb, Deborah A. Zajchowski, and Robert L. Coleman, Gynecologic Oncology Research and Practice 2015, 2:4, 8/28/2015
• Metastatic Cancer of Cowper's Gland: A Rare Cancer Managed Successfully by Molecular Profiling.  
  Myers CE, Gatalica Z, Spinelli A, Castro M, Linden E, Sartor O, Sargent M., Case Rep Oncol. 2014 Jan 16;7(1):52-7., 2014
• Apocrine carcinoma of the breast: a comprehensive review.  
  Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z., Histol Histopathol. 2013 Nov;28(11):1393-409. Epub 2013 Jun 17., 6/13/2013
• Peripheral sensory neuropathy—fighting cold with cold  
  M. Castro, Lancet Oncology Volume 9, No. 5, p415–416, May 2008, 2008
• Pharmacogenetics in the clinic: new questions about tamoxifen  
  M. Castro, J Oncol Prac 2006 2:100, 1/1/2006
• Thymidine reduce: an antidote for pemetrexed related toxicity in the setting of acute renal failure  
  Michael Castro, J Clin Oncol 2003, 21:4066, 1/1/2003
• Cerebrospinal fluid gastrin releasing peptide in the diagnosis of leptomeningeal metastases from small cell carcinoma  
  Michael P. Castro M.D., Tom J. McDonald M.D., Stephen J. Qualman M.D. andThomas M. Odorisio M.D., Cancer Volume 91, Issue 11, pages 2122–2126, 1 June 2001, 5/31/2001
• Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature  
  M P Castro, J Vanauken P, Spencer-CisekS, LeghaR, W Sponzo, Cancer 1999 Vol 85 (1055-1059), 1999
• Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report  
  MP Castro, Fodor L, Orlandi L, Cancer 1998 Vol 82 (639-641), 1/1/1998
• Join now to see all

Books/Book Chapters

• Heme-Onc Secrets 
  Chapter: Targeted Therapy 
  Michael CastroEditors: M. WOOD.UNIVERSITY OF VERMONT PRESS, Burlington2003

Abstracts/Posters

• Predictions of overall survival (OS) and progression-free survival (PFS) for specific therapeutic interventions in newly diagnosed glioblastoma multiforme (GBM) using ...
  Ahluwalia MS, Castro MP, Watson D, et al., Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 2053-2053., Chicago, 6/2022
• The impact of mismatch repair deficiency (MMRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma.
  Michael Castro, Fabio Iwamoto, Manmeet Ahluwalia, et al., Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii116–vii117, Tampa, FL, 11/2022
• Superior overall survival and disease free survival predictions for patients with glioblastoma multiform (GBM) using Cellworks Singula™ myCare-022-03
  Wen PY, Castro M, Watson D et  al, ASCO / J Clin Oncol 39 (suppl 15; abstr 2017), Chicago, 6/2021
• Cellworks singula therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: MyCare-004.
  Smyth EC, Watson D, Nutzinger B, Castro MP., ASCO / Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 4064-4064., Chicago, 6/2022
• Biosimulation Using the Cellworks Computational Omics Biology Model (CBM)-Based Assessment of Cytarabine (ARA-C) and Anthracycline Response and Novel Biomarker Respons...
  M. Castro, et al, ASH / 2021, #1299 (152645), Atlanta, 12/2021
• Cellworks Omits Biology Model (CBM predicts therapy response and identifies novel biomarkers for carboplatin/cisplatin along with pemetrexed in NSCLC patients.
  Kumar A, Velchecti, Castro M., et al., ASCO / Journal of Clinical Oncology 39, no. 15_suppl, e21211), ASCO, 6/2021
• Cellworks Omits Biology Model (CBM predicts therapy response and identifies novel biomarkers for 5FU-based combinations therapy in gastric cancer patients.
  Kumar A, Velcheti V, Castro M, et al., ASCO / Journal of Clinical Oncology 39, no. 15_suppl, ), Chicago, 6/2021
• Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.
  Castro M, Kumar A, Grover H, et al., ASCO / Journal of Clinical Oncology 39, no. 15_suppl, e21208), Chicago, 6/2021
• Superior overall survival, progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks...
  Velcheti V, Castro M, Watson D, Kapoor S, et al., ASCO / Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 9117-9117, Chicago, 6/2021
• IMMUNOMIC ANALYSIS OF GLIOBLASTOMA (GBM) USING GENE EXPRESSION PROFILING
  Michael Castro, Nilofar Badra-Azar, Thomas Kessler, Moritz Schütte, Bodo Lange, Marie-Laure Yaspo, SNO / Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii5, 11/2020
• GLUTAMATE RECEPTOR AND GLUTAMINE METABOLISM PROFILING BY GENE EXPRESSION ANALYSIS AMONG PATIENTS WITH HIGH GRADE GLIOMA (HGG)
  Michael Castro, Nilofar Badra-Azar, Thomas Kessler, Moritz Schütte, Bodo Lange, Marie-Laure Yaspo, SNO / Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii11, 11/2020
• Expression patterns of a taxane sensitivity panel in 25,000 cancer patients.
  Brian L. Abbott, Rebecca Feldman, Sandeep K. Reddy, Michael Castro, J Clin Oncol 33, 2015 (suppl; abstr e22235), 2015 ASCO Annual Meeting, 6/2015
• Drug efflux pump expression in 50,000 molecularly-profiled cancer patients.
  Rebecca Feldman, Brian L. Abbott, Sandeep K. Reddy, Michael Castro, J Clin Oncol 33, 2015 (suppl; abstr 11108), 2015 ASCO Annual Meeting, 6/2015
• Biomarker analysis of glioblastoma and potential implications for therapy.
  Joanne Xiu, Rebecca Anne Feldman-Moreno, David Arguello, Zoran Gatalica, Anatole Ghazalpour, Ryan P. Bender, Michael Castro, Sandeep K. Reddy, Gargi Dan Basu, Les Paul, J Clin Oncol 31, 2013 (suppl; abstr 2041), 2013 ASCO Annual Meeting, 6/2013
• Potential impact of different methodologies for detecting EGFR mutations in selecting chemotherapy for patients with lung cancer.
  Ryan P. Bender, Anatole Ghazalpour, Zheng Tan, Zoran Gatalica, Les Paul, Sandeep K. Reddy, Michael Castro, J Clin Oncol 31, 2013 (suppl; abstr e19006), 2013 ASCO Annual Meeting, 6/2013
• Pharmacokinetics of BSI-201, A poly (ADP-ribose) polymerase-1 (PARP1) inhibitor in cerebrospinal fluid of a breast cancer patient with carcinomatous meningitis.
  M Castro, L Li, TE Stallings., PROC AM SOC CLIN ONCOL 2010, ABSTRACT 48374, ASCO Annual Meeting 2010, 6/2010
• Pharmacogenetic correlates of benefit from gemcitabine and platinum in patients with advanced bladder cancer.
  M CASTRO, A NEUMANN, M KONICHEXKY, K DANNENBERG, S STEMMER, PROC AM SOC CLIN ONCOL 2004 ABSTRACT 3203, ASCO Annual Meeting 2004, 6/1/2004
• Successful use of anti-CD20 monoclonal antibody, Rituxan, in patients with non-Hodgkins lymphoma and renal insufficiency
  CASTRO MP, VANAUKEN J, SPONZO RW., AM SOC CLIN ONCOL 2001, 20:3325., ASCO Annual Meeting 2001, 6/1/2001
• Impact of risk stratification on mammographic interpretation.
  R SPONZO, T ASHIKAGA, C HOWLAND, P CISEK, MP CASTRO, PROC AM SOC CLIN ONCOL 2000, 19:335., ASCO Annual Meeting 2000, 6/1/2000
• Join now to see all

Lectures

• Personalized Medicine in Oncology: Recent Updates 

Other

• TIMING IS EVERYTHING OR COULD BE. 
  M. Castro, J CLIN ONCOL 21: 755, 2003.
  http://hwmaint.jco.ascopubs.org/cgi/content/full/21/4/755-a
  2003
• THE SIMPLETON’S ERROR IN DRUG DEVELOPMENT. 
  M. Castro, J CLIN ONCOL 2002 20: 4606-7.
  http://jco.ascopubs.org/content/20/23/4606
• ENILURACIL’S NEED FOR A TARGETED APPROACH: A LESSON IN DRUG DEVELOPMENT 
  M. Castro, J CLIN ONCOL 2002 20: 3750.
  http://hwmaint.jco.ascopubs.org/cgi/content/full/20/17/3750
  2002